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a b s t r a c t
Diabetic neuropathy is one of themost frequent complications of diabetesmellitus. Therefore, the
present studywas designed to investigate the anti-hyperalgesicmechanism of fentanyl in amouse
model of streptozotocin-induced diabetic neuropathy. The antinociceptive responsewas assessed by
recording the latency ina tail-ﬂick test.The tail-ﬂick latency indiabeticmicewassigniﬁcantlyshorter
than that innon-diabeticmice. Fentanyl, atdosesof3 and10μg/kg, s.c.,produced adose-dependent
increase in the tail-ﬂick latencies in diabeticmice.While fentanyl (3μg/kg, s.c.) did not produce a
signiﬁcant inhibitionof the tail-ﬂick response innon-diabeticmice, it signiﬁcantlyprolonged the tail-
ﬂick latency indiabeticmice to the same levelas thebaseline latency innon-diabeticmice.Although
pretreatmentwithnaloxone(3mg/kg, J.Q.)completelyantagonizedfentanyl-inducedantinociceptionin
non-diabetic mice, it had no effect on the antinociceptive effect of fentanyl in diabetic mice.
Pretreatmentwith either of the voltage-gated sodium channel openers fenvarelarte and veratridine
practically abolished the antinociceptive effects of fentanyl in diabetic mice. However, neither
fenvarelatenor veratridine affected the antinociceptive effect of fentanyl innon-diabeticmice. These
resultssuggestthattheanti-hyperalgesiceffectoffentanylismediatedthroughtheblockadeofsodium
channels in diabeticmice,whereas opioid receptorsmediate the antinociceptive effect of fentanyl in
non-diabeticmice.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Diabetic patients frequently exhibit one or more types of
stimulus-evoked pain, including increased responsiveness to noxious
stimuli (hyperalgesia) as well as hyper-responsiveness to normally
innocuous stimuli (allodynia). In animal models of diabetes, hyper-
algesia in response to non-noxious thermal stimulation as well as
tactile allodynia has been observed (Calcutt et al., 1996; Fox et al.,
1999; Malcangio and Tomlinson, 1998). In diabetic rats with hyper-
algesia, dorsal root ganglion (DRG) neurons display an increased
frequency of action potential generation in response to sustained
suprathreshold mechanical stimulation (Ahlgren and Levine, 1993,
1994; Ahlgren et al., 1997; Fox et al., 1999; Malcangio and Tomlinson,
1998) and increased spontaneous activity (Said, 1996). Voltage-
gated sodium channels generate and propagate action potentials in
excitable cells. Based on the differences in their sensitivity to
tetrodotoxin (TTX), sodium currents in DRG neurons are classiﬁed
into TTX-sensitive (TTX-S) and TTX-resistant (TTX-R) components
(Caffrey et al., 1992; Kostyuk et al., 1981; Roy and Narahashi, 1992).
At least two TTX-S sodium channel α-subunits, Nav1.6 and Nav1.7, are
constitutively expressed in the peripheral nervous system (Ogata and
Ohishi, 2002). In addition, the expression of Nav1.7, a TTX-S sodium
channel in DRG, is up-regulated in painful diabetic neuropathy (Hong
et al., 2004). Two TTX-R sodium channels, Nav1.8 (Akopian et al.,
1996) and Nav1.9 (Dib-Hajj, et al., 1998; Tate et al., 1998), have been
identiﬁed in DRG neurons, and changes in their expression levels
have been implicated in painful diabetic neuropathy (Coward et al.,
2000; Hirade et al., 1999; Novakovic, et al., 1998; Waxman, 1999).
Although morphine, a typical opioid analgesic, has been widely
used to treat patients with acute and chronic pain, it is often
ineffective in the treatment of diabetic neuropathic pain (Wright,
1994; Boulton et al., 1998; Adriaensen et al., 2005). In this regard,
we previously reported that the antinociceptive effects of the i.c.v.
administration of μ-opioid receptor agonists, such as morphine,
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[D-Ala2,N-MePhe4, Gly-ol5]enkephalin (DAMGO) and endomor-
phin-2, in diabetic mice were less than those in non-diabetic mice
(Kamei et al., 1992a, 1992b, 1994, 2000; Ohsawa and Kamei, 1997).
Some studies have suggested that fentanyl blocks voltage-gated
sodium channels, preferentially in slow-inactivated conformations
(Haeseler et al., 2006; Hashimoto et al., 2009). However, these studies
also indicated that the blocking effect of morphine on these sodium
channels, if present, is very weak. In this regard, Hashimoto et al.
(2009) used whole-cell voltage-clamp recording and found that, as
with lidocaine, extracellular application of fentanyl produced a
concentration-dependent suppression of sodium currents, which
was not inﬂuenced by the opioid receptor antagonist naloxone. In
agreement with these ﬁndings, fentanyl suppressed sodium currents
in thalamic neurons obtained from μ-opioid receptor knockout mice
(Hashimoto et al., 2009). Moreover, endogenous μ-opioid peptides did
not affect the amplitude of sodium currents (Hashimoto et al., 2009).
Based on these ﬁndings, it is possible that fentanyl effectively reversed
painful diabetic neuropathy by blocking sodium channels.
Therefore, to clarify this possibility, we examined the effects of
the opioid receptor antagonist naloxone and the sodium channel
openers veratridine and fenvarelate on the antinociceptive effects
of fentanyl in both non-diabetic and diabetic mice.
2. Materials and methods
This study was carried out in accordance with the Declaration of
Helsinki and/or with the guide for the committee on the care and use
of laboratory animals of Hoshi University, Tokyo, which is accredited
by the Ministry of Education, Science, Sports and Culture.
2.1. Animals
Male 4-week-old ICR mice (Tokyo Animal Laboratory Inc.,
Tokyo) weighing about 20 g at the start of the experiment were
used. The mice had free access to food and water and were housed
ﬁve per cage in an animal room that was maintained at 2471 1C
with a 12-h dark/light cycle. All behavioral experiments were
performed between 10:00 and 19:00 each day.
2.2. Induction of diabetes with streptozotocin
Mice were rendered diabetic by an intravenous injection of
streptozotocin (200 mg/kg) prepared in 0.1 N citrate buffer at
pH 4.5. Age-matched animals were injected with vehicle alone.
Experiments were conducted two weeks after the administration
of streptozotocin. Animals with a serum glucose level exceeding
400 mg/dl were considered diabetic.
2.3. Assessment of thermal hyperalgesia
The antihyperalgesic response was evaluated using the tail-ﬂick
test (KN-205E Thermal Analgesimeter, Natume, Tokyo, Japan). Brieﬂy,
the mouse was gently restrained in a tube. The tail was positioned in a
groove underneath a 50W projection bulb with the dorsal part of the
tail facing the light bulb. The light and timer were monitored with the
same switch. Twitching or movement of the tail is a typical response
elicited by heat. When this occurred, light reached a photocell and the
light and timer were switched off. Latencies were determined as the
mean of two trials. The voltage of the 50W projection lamp was set to
50 V (Ohsawa and Kamei, 1999), which gave a baseline value in non-
diabetic animals of 10–14 s. The cut-off time was set to 30 s to prevent
injury to the tail. Tail-ﬂick latencies were measured before and 30, 60
and 90min after the injection of drugs.
2.4. Intrathecal injections
Sodium channel openers and fentanyl were administered by i.t.
injection as described by Hylden and Wilcox (1980) using a 25 μl
Gastights syringe (Hamilton, USA) and a BD Precisionglides 30G
1/2 in needle (Becton Dickinson, USA). The mouse was restrained
manually and the needle was inserted between the L5 and L6
vertebrae. This site is near the end of the spinal cord and
minimizes the risk of spinal damage (Hylden and Wilcox, 1980).
The drug solution was injected in a volume of 4 μl per mouse.
Groups of mice were pretreated i.t. with each sodium channel
openers 10 min prior to fentanyl injection.
2.5. Drugs
Fentanyl hydrochloride and fenvalerate were purchased from
Covidien Japan Inc. (Tokyo, Japan) and Calbiochem-Novabiochem
Corporation (La Jolla, CA, USA), respectively. Veratridine, naloxone
and streptozotocin were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Fentanyl and naloxone were dissolved in saline. The
dose of fentanyl was determined according to the previously
report (Syzuki et al., 2005). Fenvalerate and veratridine were
dissolved in 0.4% DMSO and 0.4% ethanol in saline, respectively.
The volume of drug solutions for systemic (s.c., i.p., i.v.) injection
was 0.1 ml/10 g of mouse body weight.
2.6. Data analysis
The data are expressed as means7S.E.M. for 10 mice in each
group. The statistical signiﬁcance of differences between groups
was assessed with a 2-way analysis of variance (ANOVA) followed
by the Bonferroni/Dunnet test.
3. Results
3.1. Antinociceptive effects of fentanyl in non-diabetic and diabetic
mice
Diabetic mice had lower nociceptive threshold values than
those of non-diabetic mice, as evidenced by a signiﬁcant
(Po0.05) difference in the tail-ﬂick latency between the two
groups (diabetic mice, 6.570.7 s; non-diabetic mice, 11.670.3 s).
Fig. 1(A) shows the time course of the antinociception produced
by s.c. administration of fentanyl, at a dose of 10 μg/kg, in both
non-diabetic and diabetic mice. The antinocieptive effect of
fentanyl reached a peak 30 min after administration and then
decreased in both non-diabetic and diabetic mice. Thus, a time
interval of 30 min after administration was chosen for experi-
ments designed to quantify the antinociceptive effect of fentanyl.
As shown in Fig. 1(B) and (C), although fentanyl at a dose of
3 μg/kg, s.c., has no effect on the tail-ﬂick latencies in non-diabetic
mice, those in diabetic mice are signiﬁcantly prolonged. On the
other hand, s.c. administration of fentanyl, at a dose of 10 μg/kg,
did not cause any behavioral changes in both non-diabetic and
diabetic mice.
3.2. Effects of naloxone on the antinociceptive effects of fentanyl in
non-diabetic and diabetic mice
We assessed the effects of naloxone, an opioid receptor
antagonist, on fentanyl-induced prolongation of the tail-ﬂick
latency in non-diabetic and diabetic mice. As shown in Fig. 2,
treatment with naloxone (3 mg/kg, i.p.) completely abolishes the
fentanyl-induced prolongation of the tail-ﬂick latency in non-
diabetic mice. In diabetic mice, in contrast, pretreatment with
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naloxone (3 mg/kg, i.p.) had no effect on the fentanyl-induced
prolongation of the tail-ﬂick latency (Fig. 2).
3.3. Effects of sodium channel openers on the antinociceptive effects
of fentanyl in non-diabetic and diabetic mice
We further assessed the effects of fenvarelate and veratridine,
voltage-gated sodium channel openers, on fentanyl-induced pro-
longation of the tail-ﬂick latency in non-diabetic and diabetic mice.
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Fig.2.Effectsofnaloxoneon theantinociceptiveeffectof fentanyl innon-diabetic
(upperpanel)anddiabeticmice (lowerpanel).Naloxone (3mg/kg) is injected J.Q.
30minbeforetesting.Themicearetested30minbefore(pre,opencolumn)and30
minafter(post,hatchedcolumn)s.c.injectionoffentanyl(10μg/kg)usingthetail-
ﬂicktest.EachcolumnrepresentsthemeanwithS.E.M.for10mice ineachgroup.
nPo0.05vs.respectivepre-value.
Intrathecalinjectionofeitherfenvarelate(1μg)orveratridine(0.01μg)
elicitedacharacteristicbehavioralsyndromethatmainlyconsistedof
reciprocalhind limb scratchingdirected towards caudalpartsof the
bodyandbitingor lickingof thehind legs inmice.Thesebehavioral
responses induced by both fenvalerate and veratridine peaked at
5min  and  almost  disappeared  10min  after  injection.  Indeed,  i.t.
injection of either fenvarelate (1μg) or veratridine (0.01μg) hadno
signiﬁcant effect on the tail-ﬂick latency in both non-diabeticmice
(before fenvarelate,11.370.2s, n¼20, after fenvarelate,11.370.2s,
n¼20; before veratridine, 11.570.2s, n¼20, after veratridine,
11.270.3s,n¼20) anddiabeticmice (before fenvarelate,7.270.1s,
n¼20, after fenvarelate, 7.170.1s, n¼20; before veratridine,
7.070.1s, n¼20, after veratridine, 7.170.2s, n¼20). Therefore, in
subsequent experimentsmice were observed for 10min after the
injectionoffenvalerateorveratridine.
Fig. 1. Time course (A) and dose-response effect (B, C) of the antinociception
induced by fentanyl in non-diabetic and diabetic mice. (A) The antinociceptive
effect of fentanyl (10 μg, diabetic mice: closed circle; non-diabetic mice: closed
triangle) is assessed in the tail-ﬂick test 30, 60 and 90 min after s.c. injection.
(B) and (C) The antinociceptive effects of fentanyl, at doses of 3 and 10 μg/kg are
assessed 30 min before (pre, open column) and 30 min after (post, hatched
column) s.c. injection of fentanyl, using the tail-ﬂick test in non-diabetic (B) and
diabetic (C) mice. Each point or column represents the mean with S.E.M. for 10
mice in each group. nPo0.05 vs. the value for respective saline (SAL)-treated group
(open column or open symbol) in (A) or pre-value (B, C).
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As shown in Fig. 3 (upper panel), neither fenvarelate nor
veratridine affects s.c. administered fentanyl-induced prolongation
of the tail-ﬂick latency in non-diabetic mice. However, s.c. admi-
nistered fentanyl-induced prolongation of the tail-ﬂick latency in
diabetic mice was diminished by the pretreatment with either
fenvarelate or veratridine (Fig. 3, lower panel).
As shown in Fig. 4, i.t. administration of fentanyl, at a dose of
3 nmol, prolongs the tail-ﬂick latency in both non-diabetic mice
(upper panel) and diabetic mice (lower panel). Although pretreat-
ment with either fenvarelate or veratridine affected i.t. adminis-
tered fentanyl-induced prolongation of the tail-ﬂick latency in
non-diabetic mice (Fig. 4, upper panel), these pretreatment
diminished s.c. administered fentanyl-induced prolongation of
the tail-ﬂick latency in diabetic mice (Fig. 4, lower panel).
4. Discussion
Streptozotocin-induced diabetes in mice is considered to be an
animal model for painful diabetic neuropathy, which is an impor-
tant clinical pain condition that is used to assess the clinical
efﬁcacy of analgesic drugs (Baron et al., 2009). Heat hyperalgesia
occurs especially in mild painful diabetic neuropathy and is
suggested to be an indicator of early painful diabetic neuropathy
(Dyck et al., 2000). In streptozotocin-treated mice, heat hyperal-
gesia is seen within 1 week after the induction of diabetes
(Ohsawa et al., 2008). In the current setting, stable and robust
heat hyperalgesia for up to 2 weeks was found and repetitive
testing did not result in signs of habituation toward the heat
stimulus (Ohsawa et al., 2008). The comparison of diabetic mice
with a non-diabetic mice allows us to describe the anti-
hyperalgesic (diabetic mice) and anti-nociceptive (non-diabetic
mice) efﬁcacies of test compounds. One of the major ﬁndings of
this study is that fentanyl has an anti-hyperalgesic effect that is
enhanced under diabetic conditions. The anti-hyperalgesic effect
of fentanyl is considered to be at least partially responsible for
improving subjective symptoms in diabetic patients.
In the present study, we found that fentanyl produced anti-
nociceptive effect in non-diabetic mice and anti-hyperalgesic
effect in diabetic mice. It has been widely accepted that fentanyl
caused centrally mediated hemodynamic response, such as
hypotension and bradycardia ( Laubie et al., 1974, 1975). How-
ever, in the present study, fentanyl did not cause any behavioral
abnormality in both non-diabetic and diabetic mice. Thus,
fentanyl-induced antinociceptive effect in non-diabetic mice and
anti-hyperalgesic effect in diabetic mice are not due to the
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Fig. 3. Effects of fenvalerate and veratridine on the antinociceptive effect of fentanyl in non-diabetic (upper panel) and diabetic mice (lower panel). Fenvalerate (1 μg) and
veratridine (0.01 μg) are injected i.t. 10 min prior to fentanyl injection. The mice are tested 30 min before (pre, open column) and 30 min after (post, hatched column) s.c.
injection of fentanyl (10 μg/kg) using the tail-ﬂick test. Each column represents the mean with S.E.M. for 10 mice in each group. nPo0.05 vs. respective pre-value.
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behavioral abnormality which is caused by the hemodynamic
response to fentanyl administration.
The antinociceptive effects of s.c. administered fentanyl in non-
diabetic mice were signiﬁcantly antagonized by systemic pretreat-
ment with naloxone, a non-selective opioid receptor antagonist.
This indicates that an opioid receptor plays a role in the anti-
nociception in non-diabetic mice. On the other hand, the anti-
nociceptive effects of s.c. administered fentanyl in diabetic mice
were not antagonized by the same pretreatment. Our previous
data pointed out that the antinociceptive effects of the i.c.v.
administration of μ-opioid receptor agonists, such as morphine,
DAMGO and endomorphin-2, in diabetic mice were less than those
in non-diabetic mice (Kamei et al., 1992a, 1992b, 1994, 2000;
Ohsawa and Kamei, 1997). Fentanyl exerts its antinociceptive effect
predominantly through μ-opioid receptors (Narita et al. 2002).
Thus, these results and the present results suggest that opioid
receptors, especially μ-opioid receptors do not mediate the anti-
nociceptive effect of fentanyl at supraspinal, spinal and peripheral
sites in diabetic mice. Data from mononeuropathic pain models
suggest that reduced spinal expression of μ-opioid receptor
protein results in the limited efﬁcacy of μ-opioid receptor agonists
as measured at both the behavioral (Ossipov et al., 1995) and
cellular levels (Kohno et al., 2005). On the other hand, previous
reports have suggested that the hyposensitivity to μ-opioids in
diabetic mice arises due to a change in G-protein coupling rather
than to changes in the number of μ-opioid receptors or in the
binding function of μ-opioids (Ohsawa et al., 2000; Chen et al.,
2002; Chen and Pan, 2003). Although the detailed mechanisms are
not well deﬁned, the analgesic efﬁcacy of selective μ-opioid
receptor agonists, such as morphine, is limited under clinical
neuropathic pain conditions (Veves et al., 2008) and also in rodent
models of streptozotocin-induced diabetes (Kamei et al., 1992a,
1992b). These results and our present results suggest that certain
non-opioidergic mechanisms may be responsible for the anti-
hyperalgesic effect of fentanyl in diabetic mice.
Hong and Wiley (2006) reported that large A-ﬁber DRG
neurons demonstrated alterations in the functional properties of
TTX-S sodium current (INa) and TTX-R Nav1.9 INa, and in the levels
of sodium channel immunoreactivity in the streptozotocin-
induced model of diabetic neuropathy. Total INa, TTX-S INa, and
ramp current were signiﬁcantly increased, and the voltage-
dependent activation kinetics were shifted in the hyperpolarizing
direction in most large DRG neurons in diabetic rats. The current
associated with TTX-R Nav1.9 INa but not Nav1.8 INa was also
signiﬁcantly increased in large-soma diabetic DRG neurons. Cor-
respondingly, the percentage of large-soma DRG neurons
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Fig. 4. Effects of fenvalerate and veratridine on the antinociceptive effect of i.t. administered fentanyl in non-diabetic (upper panel) and diabeticmice (lower panel).
Fenvalerate(1μg)andveratridine(0.01μg)areinjectedi.t.10minpriortofentanylinjection.Themicearetested30minbefore(pre,opencolumn)and30minafter(post,
hatchedcolumn)i.t.injectionoffentanyl(03nmol)usingthetail-ﬂicktest.EachcolumnrepresentsthemeanwithS.E.M.for10miceineachgroup.nPo0.05vs.respective
pre-value.
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expressing TTX-S Nav1.2, Nav1.3, Nav1.7, and TTX-R Nav1.9 sig-
niﬁcantly increased in diabetic animals, suggesting that these
alterations may underlie the increased sodium currents in diabetic
rats. In fact, some sodium channel blockers, such as lidocaine and
mexiletine, effectively prevent the tactile allodynia associated with
diabetes-induced neuropathy under clinical diabetic neuropathic
pain conditions (Viola et al., 2006; Wolff et al., 2010; Dejgard et al.,
1988; Oskarsson et al., 1997) and in rodent models of painful
diabetic neuropathy (Kamei et al., 1995; Suzuki et al., 2011). In this
regard, interestingly, the sodium channel openers fenvalerate and
veratridine antagonized the anti-hyperalgesic effect of fentanyl in
diabetic mice, but had no effect on the antinociception induced
by fentanyl in non-diabetic mice. Hashimoto et al. (2009) used
whole-cell voltage-clamp recording and found that, as with
lidocaine, extracellular application of fentanyl produced a concen-
tration-dependent suppression of sodium currents, which was not
inﬂuenced by the opioid receptor antagonist naloxone. Further-
more, the suppressive effect of fentanyl on sodium currents was
clearly observed in thalamic neurons obtained from μ-opioid
receptor knockout mice. Moreover, endogenous μ-opioid peptides
did not affect the amplitude of sodium currents. Based on these
results, the authors concluded that fentanyl suppresses thalamic
sodium currents through non-opioidergic mechanisms. They also
found that the extracellular application of fentanyl had a much
greater inhibitory effect than the application of morphine and
oxycodone, and this effect was comparable to that of lidocaine
(Hashimoto et al., 2009). Furthermore, Lefﬂer et al. (2012) also
reported that although morphine and fentanyl produced
concentration-dependent block of TTX-R sodium channels in the
DRG neuroblastoma hybridoma cell line (ND7/23), fentanyl has
about 4-fold afﬁnity for TTX-R sodium channels compared to that
of morphine. These results and our present data strongly indicate
that blockade of sodium channels may play a role in the anti-
hyperalgesic effect of fentanyl in diabetic mice.
In conclusion, we have shown that fentanyl produced an anti-
hyperalgesic effect in diabetic mice without opioid receptor activation.
Furthermore, our data suggest that the anti-hyperalgesic effect of
fentanyl is mediated by the blockade of sodium channels in diabetic
mice, whereas opioid receptors mediate the antinociceptive effect of
fentanyl in non-diabetic mice.
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Abstract: The present study investigated the effects of intrathecal administration of 
ProTx-II (tarantula venom peptide) and A803467 (5-[4-chloro-phenyl]-furan-2-carboxylic 
acid [3,5-dimethoxy-phenyl]-amide), selective Nav1.7 and Nav1.8 antagonists, respectively, on 
thermal hyperalgesia in a painful diabetic neuropathy model of mice. Intrathecal administra-
tion of ProTx-II at doses from 0.04 to 4 ng to diabetic mice dose-dependently and significantly 
increased the tail-flick latency. Intrathecal administration of A803467 at doses from 10 to 100 ng 
to diabetic mice also dose-dependently and significantly increased the tail-flick latency. However, 
intrathecal administration of either ProTx-II (4 ng) or A803467 (100 ng) had no effect on the 
tail-flick latency in nondiabetic mice. The expression of either the Nav1.7 or Nav1.8 sodium 
channel protein in the dorsal root ganglion in diabetic mice was not different from that in nondia-
betic mice. The present results suggest that ProTx-II and A803467, highly selective blockers of 
Nav1.7 and Nav1.8 sodium channels, respectively, in the spinal cord, can have antihyperalgesic 
effects in diabetic mice.
Keywords: painful diabetic neuropathy, Nav1.7, Nav1.8, ProTx-II, A803467
Introduction
Painful neuropathy is one of the most frequent complications of diabetes mellitus. 
Streptozotocin (STZ)-induced diabetes in rodents has been extensively used to study 
neuropathic pain and to explore the efficacies of new potential therapeutic drugs through 
the use of sensory behavioral tests. Diabetic neuropathy can be easily identified in this 
model through associated sensory dysfunctions, including thermal hyperalgesia and 
mechanical allodynia in rodents.1–3
Sodium channel blockade is one of the best-known treatments for relieving 
 diabetes-induced pain. Some sodium-channel blockers, such as lidocaine and 
mexiletine, effectively prevent the tactile allodynia associated with diabetes-induced 
neuropathy under clinical diabetic neuropathic pain conditions4–7 and in rodent 
models of painful diabetic neuropathy.8,9 At least nine different voltage-dependent 
sodium-channel subtypes (Nav1.1–1.9) have been identified in the nervous system. 
Each voltage-dependent sodium-channel subtype can be classified functionally as 
either tetrodotoxin (TTX)-sensitive (fast inactivating) (TTX-S) or -resistant (slow 
 inactivating) (TTX-R).10–12 Seven of these subtypes are expressed in sensory neurons 
in the dorsal root ganglion (DRG), and peripheral nerve injury can alter the expression 
patterns of several types of voltage-gated sodium channels.13–15 Recently, voltage-gated 
sodium channels, especially Nav1.7 and Nav1.8, have been implicated in chronic neu-
ropathic pain.16,17 These subtypes are expressed in small nociceptive fibers, and can be 
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down- or upregulated under painful conditions.18,19 It is well 
recognized that Nav1.7 is a TTX-S channel and Nav1.8 is 
TTX-R.16,19 These channels are coexpressed in nociceptive 
neurons of the DRG.20 Nav1.7 may be involved in the initial 
phase of depolarization, and initiates action potentials.20 
Action potentials are maintained by Nav1.8 and this is fol-
lowed by hyperpolarization of the membrane.20
The precise roles of spinal Nav1.7 and Nav1.8 in the main-
tenance of thermal hyperalgesia in diabetic neuropathy are not 
clear. The present study investigated if intrathecal (IT) admin-
istration of ProTx-II (cystine knot peptides from tarantula 
venom) and A803467 (5-[4-chloro-phenyl]-furan-2-carboxylic 
acid [3,5-dimethoxy-phenyl]-amide), selective Nav1.7 and 
Nav1.8 antagonists, respectively, could reduce thermal hype-
ralgesia in a mouse model of diabetic neuropathy.21,22
Materials and methods
Animals
Male 4-week-old ICR mice (Tokyo Animal Laboratory Inc., 
Tokyo, Japan), weighing about 20 g at the start of the experi-
ment, were used. The mice had free access to food and water 
and were housed five per cage in an animal room that was 
maintained at 24oCp1oC with a 12-hour dark/light cycle. All 
behavioral experiments were performed between 10 am and 
7 pm each day. This study was carried out in accordance with 
the Declaration of Helsinki and/or according to the guidelines 
of the committee on the care and use of laboratory animals of 
Hoshi University, Tokyo, which is accredited by the Ministry 
of Education, Science, Sports and Culture.
Induction of diabetes with STZ
Mice were rendered diabetic by an intravenous injection 
of STZ (200 mg/kg) prepared in citrate buffer at pH 4.5. 
Age-matched animals were injected with vehicle alone. 
Experiments were conducted 2 weeks after the admin-
istration of STZ. Animals with a serum glucose level 
above 400 mg/dL were considered diabetic.
Assessment of thermal hyperalgesia
The antihyperalgesic response was evaluated using the 
tail-flick test (KN-205E Thermal Analgesimeter; Natume, 
Tokyo, Japan). Briefly, the mouse was gently restrained 
in a tube. The tail was positioned in a groove underneath a 
50 W projection bulb with the dorsal part of the tail facing 
the light bulb. The light and timer were monitored with the 
same switch. Twitching or movement of the tail is a typical 
response elicited by heat. When this occurred, light reached 
a photocell and the light and timer were switched off. 
 Latencies of such movement were determined as the mean 
of two trials. The voltage of a 50 W projection lamp was set 
to 50 V, which gave a baseline value in nondiabetic animals 
of 10–14 seconds.3 The cut-off time was set to 30 seconds to 
prevent injury to the tail. Tail-flick latencies were measured 
before and 15, 30, 60, 90, 120, 150, and 180 minutes after 
the injection of drugs.
IT injections
Sodium-channel blockers were administered by IT injection 
as described by Hylden and Wilcox23 using a 25 ML Gastight® 
syringe (Hamilton, Reno, NV USA) and a BD Precisionglide® 
30G 1/2 inch needle (Becton Dickinson, Franklin Lakes, NJ, 
USA). The mouse was restrained manually and the needle 
was inserted between the L5 and L6 vertebrae. This site is 
near the end of the spinal cord and minimizes the risk of 
spinal damage.23 The drug solution was injected in a volume 
of 4 ML per mouse.
Western blotting
The DRG was quickly dissected 2 weeks after the administra-
tion of STZ. Western blotting was performed as described 
previously24 with some modifications. Briefly, the DRG was 
homogenized in ice-cold radioimmunoprecipitation assay 
buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 
0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxy-
cholate, 1% Triton X, 1 mM phenylmethylsulfonyl fluoride, 
25 Mg/mL leupeptin, 25 Mg/mL aprotinin, 10 mM NaF, and 
1 mM Na3VO4. The homogenate was then centrifuged at 
20,000s g for 20 minutes at 4oC, and the supernatant was 
retained as total tissue lysate. The protein concentration was 
measured using a BCA assay kit (Thermo Fisher Scientific 
Inc., Waltham, MA, USA). Samples were diluted with radio-
immunoprecipitation assay buffer to achieve the same con-
centration of protein (15 Mg/5 ML). Samples were diluted with 
an equal volume of 2s electrophoresis sample buffer contain-
ing 2% SDS and 10% glycerol with 0.2 M dithiothreitol. 
Proteins were separated by SDS-PAGE (5%–20% gradient 
gel; Atto, Tokyo, Japan). After electrophoresis, proteins 
were transferred to a nitrocellulose membrane (Amersham 
Life Science, Arlington Heights, IL, USA) in Tris/glycine 
buffer containing 100 mM Tris, 192 mM glycine, and 5% 
methanol. The membrane was soaked in a blocking buffer 
(5% bovine serum albumin in Tris-buffered saline [TBS] 
[pH 7.6] containing 0.1% Tween-20 [TBS/T]) for 60 minutes 
at room temperature. The membrane was immunoblotted 
overnight at 4oC with rabbit antibodies against Nav1.7 
(1:500; Alomone Labs, Jerusalem, Israel) and Nav1.8 (1:500; 
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Sigma-Aldrich Co, St Louis, MO, USA). The membrane 
was then washed in TBS/T three times at 10-minute inter-
vals and incubated in horseradish peroxidase-conjugated 
goat anti-rabbit IgG (1:20,000; Cell Signaling Technology, 
Beverly, MA, USA) for 90 minutes at room temperature. 
After the membranes were washed in TBS/T five times at 
5-minute intervals and in TBS twice at 5-minute intervals, 
the antigen–antibody peroxidase complex was detected by 
enhanced chemiluminescence (Thermo Fisher Scientific) 
and immunoreactive bands were  visualized by Light Capture 
(AE-6981C; Atto). The membranes were washed again in 
blocking buffer containing 0.1% sodium azide and incubated 
with antibody against GAPDH (1:100,000; Merck Mil-
lipore,  Billerica, MA, USA) overnight at 4oC with gentle 
 agitation.  Membranes were incubated with second antibody, 
and image development was performed. The intensity of the 
band was analyzed and semiquantified by computer-assisted 
densitometry using a CS analyzer (Atto). Values for Nav1.7 
and Nav1.8 in mice DRG were normalized by the respective 
value for GAPDH.
Drugs
Tarantula venom peptide ProTx-II, which selectively interacts 
with Nav1.7 sodium channel, was purchased from Peptide 
Institute Inc. (Ibaraki, Osaka, Japan). (5-[4-chloro-phenyl]-
furan2-carboxylic acid [3,5-dimethoxy-phenyl]-amide 
(A803467), a selective Nav1.8 sodium channel blocker, and 
STZ were purchased from Sigma-Aldrich Co. ProTx-II was 
dissolved in saline. A803467 was dissolved in 30% dimethyl 
sulfoxide (DMSO) in saline. For vehicle-only control groups, 
equal volumes of DMSO or saline were injected.
Data analysis
The data are expressed as means p standard error for ten 
mice in each group. The statistical significance of differences 
between groups was assessed with a two-way analysis of 
variance followed by the Bonferroni/Dunnett test.
Results
Thermal hyperalgesia in STZ- 
induced diabetic mice
To determine thermal hyperalgesia, all mice were examined 
with regard to their tail-flick responses to noxious thermal 
stimulation before and after STZ administration. Diabetic 
mice had lower nociceptive threshold values than did nondia-
betic mice, as evidenced by a significant (P0.05) difference 
in the tail-flick latency between the two groups (diabetic mice, 
6.5p0.7 seconds; nondiabetic mice, 11.6p0.3 seconds).
Effects of IT ProTx-II and A803467  
on thermal hyperalgesia in STZ- 
induced diabetic mice
The tail-flick latencies in unmanipulated age-matched 
nondiabetic and diabetic mice did not differ from those in 
vehicle-only control rats that received IT DMSO or saline. 
Treatment with either ProTx-II, A803467, or DMSO did 
not caused abnormal behaviors in mice. Furthermore, mice 
were fully awake, were responsive to stimuli, and retained the 
righting reflex after the administration of these drugs.
IT administration of ProTx-II at doses from 0.04 to 
4 ng to diabetic mice dose-dependently and significantly 
increased the tail-flick latency. The antihyperalgesic effect 
of ProTx-II (4 ng) in diabetic mice peaked within 60 min-
utes after treatment (baseline, 6.6p0.2 seconds; 60 minutes, 
15.2p0.6 seconds) and gradually returned to baseline within 
150 minutes (Figure 1A). However, IT administration of 
ProTx-II to nondiabetic mice, even at a dose of 4 ng, did not 
significantly change the tail-flick latency (Figure 1B).
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Figure 1 Time course of the effect of ProTx-II on the thermal nociceptive threshold 
in diabetic (A) and nondiabetic (B) mice.
Notes: The antinociceptive effect of ProTx-II was assessed in the tail-ﬂick test 30, 
60, 90, 120, and 180 minutes after intrathecal injection. Each point represents the 
mean with standard error of 7–10 mice. *P0.05 versus respective vehicle (saline)-
treated group.
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After IT administration, A803467 at doses from 
10 to 100 ng to diabetic mice also dose-dependently and 
significantly increased the tail-flick latency. The antihyper-
algesic effect of A803467 (100 ng) in diabetic mice peaked 
within 30 minutes after treatment (baseline, 6.1p0.2 seconds; 
30 minutes, 14.7p0.6 seconds) and gradually returned to 
baseline within 180 minutes (Figure 2B). However, IT admin-
istration of A803467 at a dose of 100 ng had no effect on the 
tail-flick latency in nondiabetic mice (Figure 2A).
Coadministration of ProTx-II (0.4 ng, IT) and A803467 
(30 ng, IT) caused an additive antihyperalgesic effect in 
diabetic mice when the tail-flick latency was measured 
30 minutes after administration (ProTx-II alone: baseline, 
7.1p0.1 seconds; 30 minutes, 11.7p0.3 seconds, n10; 
A803467 alone: baseline, 7.0p0.2 seconds; 30 minutes, 
12.6p0.2 seconds, n10; ProTx-II plus A803467: baseline, 
6.3p0.3 seconds; 30 minutes, 16.8p0.5 seconds, n10). 
However, IT coadministration of ProTx-II and A803467 
had no effect on the tail-flick latency in nondiabetic 
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Figure 2 Time course of the effect of A803467 on the thermal nociceptive threshold 
in diabetic (A) and nondiabetic (B) mice.
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Figure 3 The protein levels of Nav1.7 (A) and Nav1.8 (B) in the dorsal root 
ganglion of nondiabetic and diabetic mice.
Notes: Immunoblots are representative of the results for Nav1.7 and Nav1.8. The 
immunoblots of Nav1.7 and Nav1.8 were normalized by GAPDH. Each column 
represents the mean with standard error of eight mice.
mice (baseline, 11.9p0.3 seconds; 30 minutes, 12.4p0.2 
seconds, n10).
Effect of diabetes on the protein  
levels of Nav1.7 and Nav1.8 sodium 
channels in DRG
Expression of the Nav1.7 and Nav1.8 sodium-channel 
proteins was examined in the spinal cords of diabetic and 
nondiabetic mice. There was no difference in the expression 
of either the Nav1.7 or Nav1.8 sodium-channel protein in the 
DRG between diabetic and nondiabetic mice (Figure 3).
Discussion
Previously, we reported that the IT administration of sodium-
channel opener fenvalerate produced characteristic behavioral 
responses which mainly consisted of hind limb scratching 
directed toward caudal parts of the body and biting or licking 
of the hind legs.25 The duration of this IT fenvalerate-induced 
characteristic behavioral response in diabetic mice was sig-
nificantly longer than that in nondiabetic mice. Furthermore, 
pretreatment with intraperitoneal morphine (1–10 mg/kg) 
dose-dependently reduced  fenvalerate-induced characteristic 
behavioral response.25 We also demonstrated that fenvalerate-
induced characteristic behavioral response was reduced by 
mexiletine (10 and 30 mg/kg, intraperitoneal), a lidocaine-
like sodium-channel blocker, in a dose-dependent manner.25 
Therefore, we suggested that fenvalerate-induced behavior 
may be related to nociception caused by the activation of 
sodium channels. However, fenvalerate is known to  modulate 
both TTX-R and TTX-S sodium channels in a similar 
 direction.26 We recently demonstrated that the fenvalerate-
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induced nociceptive response was reduced by pretreatment 
with calphostin C, a selective protein kinase C inhibitor.25 On 
the other hand, the fenvalerate-induced nociceptive response 
was enhanced by pretreatment with protein kinase C activator, 
phorbol-12, 13-dibutyrate.25 Thio and Sontheimer reported 
that the activation of protein kinase C had different effects 
on TTX-S and TTX-R sodium currents.27 They reported 
that although phorbol 12-myristate 13-acetate reduced peak 
currents of TTX-S sodium channels, it potentiated peak cur-
rent of TTX-R sodium channels.27 TTX-R current activation 
was faster and current inactivation changed from single- to 
bi-exponential after exposure to phorbol 12-myristate 13-ac-
etate.27 In contrast, TTX-S current activation was unchanged, 
and current inactivation decreased by an average of 50% 
following exposure to phorbol 12-myristate 13-acetate.27 
Similarly, it has been reported that the activation of protein 
kinase C increased TTX-R sodium current, whereas inhibi-
tors of protein kinase C decreased TTX-R sodium current.28 
These results suggest that the sensitization of TTX-R sodium 
channels, by the activation of protein kinase C, may play 
an important role in the enhancement of the duration of 
fenvalerate-induced nociceptive behavior in diabetic mice. 
Based on these results, we concluded that TTX-R sodium-
channel function is altered in diabetes, which explains why 
neurons that participate in nociception are highly excitable 
in diabetic animals.29 On the other hand, it has been reported 
that changes in the activities of sodium channels, particularly 
TTX-R Nav1.8 sodium channels, can play an important role 
in the progression of diabetes-induced signs of pain, such as 
thermal hyperalgesia and mechanical allodynia.14,30 A803467 
was 300- to 1,000-fold more potent at blocking Nav1.8 as 
compared with its ability to block Nav1.2, Nav1.3, Nav1.5, 
and Nav1.7.31 The present study demonstrated that IT admin-
istration of A803467, a specific Nav1.8 sodium-channel 
blocker, produced a dose-dependent antinociceptive effect 
in diabetic mice, but not in nondiabetic mice. This result 
supports the above hypothesis that TTX-R Nav1.8 sodium 
channels play an important role in the progression of painful 
diabetic neuropathy.
On the other hand, although several reports have indicated 
that animals with painful diabetic neuropathy exhibited an 
increase in protein levels of Nav1.7 sodium channel in DRG 
compared to lean controls with no pain,32–34 no previous 
study has indicated that Nav1.7 sodium-channel blockade 
has a therapeutic effect against painful diabetic neuropathy. 
Interestingly but unexpectedly, we observed that ProTx-II, 
a selective blocker of Nav1.7 sodium channels, has anti-
nociceptive effects in diabetic mice with painful neuropathy. 
Although ProTx-II inhibits multiple sodium-channel 
subtypes (Nav1.1–1.8), it has been reported to be 100-fold 
more selective for Nav1.7.35,36 Thus, our data suggest that 
Nav1.7 sodium channels contribute to thermal hyperalgesia 
in diabetic mice with painful neuropathy.
The percentage of large-soma DRG neurons that express 
TTX-S Nav1.7 significantly increased in diabetic animals, 
suggesting that these alterations may underlie the increased 
sodium currents in diabetic rats. On the other hand, TTX-R 
Nav1.8 transcription and expression are decreased in diabetic 
rats30,37 with increased TTX-R sodium currents.30,38–40 In the 
present study, however, we observed that the expression of 
both Nav1.7 and Nav1.8 in the DRG of diabetic mice did not 
differ from those in nondiabetic mice. The phosphorylation 
of Nav1.7 and Nav1.8 appears to be increased in the DRG 
of diabetic rats, suggesting that changes in serine/threonine 
and tyrosine phosphorylation of voltage-gated sodium chan-
nels may play a role in the transmission of painful stimuli 
in diabetic neuropathy.30 Changes in the function of sodium 
channels, such as sodium-channel phosphorylation, but not 
the expression of channels, may contribute to painful diabetic 
neuropathy.
In summary, the present results suggest that ProTx-II and 
A803467, highly selective blockers of Nav1.7 and Nav1.8 
sodium channels, respectively, in the spinal cord, can produce 
antihyperalgesic effects in diabetic mice. Furthermore, we 
observed that coadministration of ProTx-II (0.4 ng, IT) and 
A803467 (30 ng, IT) caused an additive antihyperalgesic 
effect in diabetic mice. These data firstly provide functional 
evidence that blockade of Nav1.7 and Nav1.8 sodium chan-
nels may be appropriate targets for treating the painful clinical 
signs of diabetes.
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